Literature DB >> 22641597

Thoracic myelopathy due to calcification of the ligamentum flavum with hyperproteinorachia and responsive to steroid therapy: case report.

Flávia Yuri Shiguematsu1, Elaine Cristina Caon de Souza, Adriana Fontes Zimmermann, Gláucio Ricardo Werner Castro, Ivânio Alves Pereira, Fabricio Souza Neves.   

Abstract

Calcification and ossification of the ligamentum flavum or of the posterior longitudinal ligament are causes of compressive myelopathy, more frequent in the lower thoracic levels, and extremely rare in Western populations. Surgical decompression is the only therapy, but the disease is usually progressive, and its recurrence after surgery is common. Inflammatory mediators might play a role in the progression of compressive myelopathy, but, to our knowledge, the therapeutic approach involving anti-inflammatory agents has never been tried before. We report a case of compressive myelopathy due to calcification of the ligamentum flavum, in which hyperproteinorachia and response to steroid therapy have been observed. Those data have not been published before and might provide new ideas for the disease understanding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641597

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  3 in total

1.  Physicochemical characterization of mineral deposits in human ligamenta flava.

Authors:  Sylwia Orzechowska; Andrzej Wróbel; Marcin Kozieł; Wiesław Łasocha; Eugeniusz Rokita
Journal:  J Bone Miner Metab       Date:  2017-04-07       Impact factor: 2.626

2.  Dorsal Spinal Ligamentum Flavum Thickening: A Magnetic Resonance Imaging Study.

Authors:  Amarnath Chelladurai; Suhasini Balasubramaniam; Sarenya Preyah Anbazhagan; Sathyan Gnanasihamani; Sukumar Ramaswami
Journal:  Asian Spine J       Date:  2018-02-07

3.  Model of Pathological Collagen Mineralization Based on Spine Ligament Calcification.

Authors:  Sylwia Orzechowska; Renata Świsłocka; Włodzimierz Lewandowski
Journal:  Materials (Basel)       Date:  2020-05-04       Impact factor: 3.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.